The Effect of Advances in Lung-Cancer Treatment on Population Mortality | NEJM
New lung cancer treatment combo approved on NHS in England - Cancer Research UK - Cancer news
New Jersey CyberKnife Develops Training Program for Multidisciplinary Approach to Lung Cancer Treatment | Toms River, NJ Patch
Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial - The Lancet Oncology
Bristol Myers Squibb's Opdivo posts another win in early lung cancer, but debate over treatment approach likely remains | FiercePharma
Cancer Institute of New Jersey Researcher Captures $80K for Lung Cancer Detection Study
SOD1 regulates ribosome biogenesis in KRAS mutant non-small cell lung cancer | Nature Communications
First in New Jersey, and One of First in Nation, to Use New Technology for Treatment of Lung Cancer - Englewood Health
24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer - Journal of Thoracic Oncology
Lung Cancer Services | Cancer Center, New Jersey | Valley Health System
Dynamic simulation of motion effects in IMAT lung SBRT – topic of research paper in Medical engineering. Download scholarly article PDF and read for free on CyberLeninka open science hub.
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial - The Lancet
Lung Cancer Patient Still Going Strong a Year After Diagnosis Thanks to New Immunotherapy | Jefferson Health New Jersey
Lung Cancer Treatment in New Jersey | RWJBarnabas Health
Homepage | Rutgers Cancer Institute of New Jersey
Advanced Metastatic Non-Small Cell Lung Cancer Information | ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound)
Cancer Treatment | Jefferson Health New Jersey
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial - The Lancet
Lung Cancer NJ | Cancer Treatment Center in NJ, Hospitals 5 Affiliated
What's New in Lung Cancer Treatments & Advanced Therapies | Jefferson Health New Jersey
Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer - Journal of Thoracic Oncology
Virtua Cancer Program: Cancer Treatment Services in NJ
Systemic Treatment Patterns With Advanced or Recurrent Non–small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study - Clinical Therapeutics
Lung Cancer Basics | American Lung Association
Lung Cancer Treatment
Homepage | Rutgers Cancer Institute of New Jersey
